Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified-release hydrocortisone versus conventional thrice-daily hydrocortisone in primary adrenal insufficiency
2006-007084-89Phase 2Completed
- Sponsor
- DuoCort
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hydrocortisone in Addison's disease (2 arms), sponsored by DuoCort. Primary endpoints: Difference in total serum cortisol AUC0-24h between once-daily and thrice-daily therapy and Safety and efficacy of modified-release hydrocortisone versus conventional therapy. Started Feb 2007; status: completed.
02
Drugs
hydrocortisone
03
Conditions
Addison's disease
Beyond the preview
Go deeper on 2006-007084-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007084-89.